Charles Russell Speechlys advises Kreos Capital on its €15 million growth capital investment
Charles Russell Speechlys LLP advised Kreos Capital V (UK) Limited on its €15 million growth capital investment in Kiadis Pharma NV (“Kiadis Pharma”), a Dutch company listed on Euronext Amsterdam and Euronext Brussels.
Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders. Its product candidates have the potential to make allogeneic hematopoietic stem cell transplantations (HSCT) safer and more effective for patients.
Kiadis Pharma announced to the market that it will use the financing to advance the development of its ATIR products, for general corporate purposes and to repay €5.3 million of existing Dutch Government Loans.
The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Senior Associate) and Amelly Kok (Associate) from our Corporate Team. Fruytier Lawyers in Business advised on matters of Dutch law and Borden Ladner Gervais LLP on matters of Canadian law respectively.
News & Insights
Market Abuse Regulation Breakfast, 25 April 2018
Discussing developments and practical approaches to issues that have arisen since MAR came into force.
Charles Russell Speechlys advises discoverIE Group plc on Dutch manufacturer Santon Group
Santon is a Dutch based designer and manufacturer of custom switches for electronic applications.
Charles Russell Speechlys advises management of MRH on £1.2 billion MRH sale
Together, MRH and MFG will operate more than 900 petrol and convenience retail sites across the UK.
Charles Russell Speechlys builds Paris practice with Corporate partner hire
Charles Russell Speechlys is strengthening its corporate practice in Paris with the hire of Corporate M&A partner Sandrine de Sousa.